Core Viewpoint - Dongwu Securities report indicates that Jingxin Pharmaceutical focuses on the fields of mental neurology and cardiovascular health, with a positive outlook on its overall performance due to the clearance of finished drug procurement, stabilization of raw materials, and recovery in medical device growth [1] Group 1: Business Focus - Jingxin Pharmaceutical is concentrating on the mental neurology and cardiovascular sectors, which are expected to drive future growth [1] - The company has successfully launched the insomnia drug Dazisni, which is anticipated to gain market traction [1] Group 2: Product Development - The small molecule Lp(a) inhibitor for lowering lipids is progressing well in its research and development, showing potential for international market expansion [1] - The company is expected to see a continuous rollout of innovative drugs, contributing to revenue growth and valuation enhancement [1] Group 3: Financial Outlook - The overall performance of the company is projected to maintain a double-digit growth rate [1] - Given the stable development of existing businesses and the promising progress in innovative drug research, the company is rated with a "buy" recommendation [1]

Core Insights - Jingxin Pharmaceutical's stock price increased by 57.99% year-to-date, but has seen a decline of 4.65% in the last five trading days and 0.81% in the last twenty days [2] - The company reported a revenue of 2.017 billion yuan for the first half of 2025, a year-on-year decrease of 6.20%, and a net profit of 388 million yuan, down 3.54% year-on-year [2] Financial Performance - As of June 30, 2025, Jingxin Pharmaceutical's total market capitalization is 16.962 billion yuan, with a trading volume of 267 million yuan and a turnover rate of 1.91% [1] - The company has cumulatively distributed 2.11 billion yuan in dividends since its A-share listing, with 801 million yuan distributed in the last three years [3] Shareholder Information - The number of shareholders as of June 30, 2025, is 25,700, a slight decrease of 0.11% from the previous period, with an average of 28,196 circulating shares per shareholder, an increase of 0.11% [2] - Hong Kong Central Clearing Limited is the fifth-largest circulating shareholder, holding 9.6492 million shares, a decrease of 15.3917 million shares from the previous period [3]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Views - The company focuses on the fields of mental health and cardiovascular diseases, with a promising development of innovative drugs. The launch of the insomnia drug, Dazisni, is expected to significantly contribute to revenue growth. The company is also advancing in the development of a small molecule Lp(a) inhibitor, which has potential for international markets [7][9]. Summary by Sections 1. Company Overview - The company has diversified its business across raw materials, finished drugs, and medical devices, marking a new phase in innovative drug development. It has become a leading enterprise in the mental health and cardiovascular sectors, with a production capacity exceeding 10 billion tablets [12][14]. 2. Financial Performance - The company’s total revenue for 2023 is projected at 3,999 million yuan, with a year-on-year growth of 5.79%. The net profit attributable to shareholders is expected to be 618.90 million yuan, reflecting a decline of 6.55% compared to the previous year. Revenue is forecasted to grow to 5,770 million yuan by 2027, with a compound annual growth rate of approximately 12.59% [1][18]. 3. Product Pipeline - The company has a rich pipeline of over ten innovative drug projects, including the small molecule Lp(a) inhibitor JX2201, which is currently in Phase I clinical trials. The drug has significant potential due to the large patient population with elevated Lp(a) levels and the absence of approved treatments targeting this condition [7][61]. 4. Market Dynamics - The insomnia drug market in China is projected to grow significantly, with the number of insomnia patients expected to reach 300 million by 2025. The company’s insomnia drug, Dazisni, is anticipated to capture a substantial market share following its launch and subsequent inclusion in the medical insurance list [45][54]. 5. Revenue Contributions - The finished drug segment is expected to contribute approximately 61% of total revenue in 2024, with a projected revenue of 25.22 billion yuan. The company is also focusing on expanding its overseas market presence and enhancing its product offerings through innovative drug development [29][35].

Investment Rating - The report maintains an "Accumulate" rating for the company [6][13]. Core Views - The company's Q2 2025 non-GAAP profit exceeded expectations, driven by the volume increase of Didasun and the gradual advancement of its innovative pipeline, indicating a positive outlook for its transformation into innovation [2][13]. Financial Summary - Total revenue for H1 2025 was 2.017 billion yuan, a decrease of 6.2% year-on-year, while net profit attributable to the parent company was 388 million yuan, down 3.5%. The non-GAAP net profit was 360 million yuan, an increase of 7.8%. The gross margin was 49.6%, down 2.0 percentage points [13]. - For Q2 2025, the single-quarter revenue was 1.06 billion yuan, a decrease of 2.6%, with a net profit of 225 million yuan, down 2.7%. The non-GAAP net profit was 214 million yuan, an increase of 20.4%, and the gross margin was 51.2%, down 0.03 percentage points [13]. - The company adjusted its EPS forecasts for 2025-2026 to 0.94 and 1.09 yuan respectively, with a new forecast for 2027 at 1.30 yuan. The target price was raised to 27.25 yuan based on a 25x PE for 2026 [13]. Business Performance - The main business remains stable, with the finished drug revenue for H1 2025 at 1.175 billion yuan, down 9.7%. However, foreign trade revenue grew over 30.1%. The innovative drug Didasun had its first year of insurance coverage, generating 55 million yuan in revenue during the reporting period [13]. - The raw material drug segment reported revenue of 453 million yuan, down 9.6%, while the medical device segment saw revenue of 349 million yuan, an increase of 12.0% [13]. Innovation Pipeline - The innovative pipeline is expected to continue catalyzing growth, with several drugs in various stages of clinical trials, including JX11502MA for schizophrenia and JX2201 for cardiovascular issues [13].

Core Viewpoint - Jingxin Pharmaceutical experienced a significant stock decline, hitting the limit down price of 17.66 yuan, with a drop of 9.07%, and a total market capitalization of 15.361 billion yuan [1] Group 1: Company Performance - The company is undergoing a business transformation, facing substantial pressure in its traditional operations, with revenues from pharmaceutical manufacturing and raw materials both declining by approximately 9.5% [1] - Operating cash flow decreased by 17.48%, with some subsidiaries reporting losses, raising concerns about the efficiency of fund utilization and high sales expenses impacting financial health [1] Group 2: Industry Environment - The pharmaceutical industry is experiencing ongoing policy changes, including centralized procurement, which may adversely affect the company's traditional business [1] - Revenue from raw materials has declined due to industry fluctuations, indicating instability in the industry environment that poses challenges for the company [1] Group 3: Market Sentiment - The company introduced a "historical high" concept, and after reaching a record high stock price, profit-taking may have triggered the decline [1] - In the current market environment, investors may prefer to avoid stocks with excessive price increases, contributing to the stock price correction [1] - The recent stock price high, coupled with negative growth, suggests existing pressure, and the limit down may incite panic selling among investors, exacerbating the stock decline [1]

Core Viewpoint - Jingxin Pharmaceutical's stock price has shown significant growth this year, with a 60.08% increase, despite a recent decline of 2.01% on September 9 [1][2]. Financial Performance - For the first half of 2025, Jingxin Pharmaceutical reported a revenue of 2.017 billion yuan, a year-on-year decrease of 6.20%, and a net profit attributable to shareholders of 388 million yuan, down 3.54% year-on-year [2]. - The company has cumulatively distributed 2.11 billion yuan in dividends since its A-share listing, with 801 million yuan distributed over the past three years [3]. Stock Market Activity - As of September 9, the stock price was 19.96 yuan per share, with a market capitalization of 17.186 billion yuan. The trading volume was 2.12 billion yuan, with a turnover rate of 1.44% [1]. - The stock has appeared on the "Dragon and Tiger List" once this year, with a net buy of 111 million yuan on July 4, accounting for 21.90% of total trading volume [1]. Shareholder Information - As of June 30, 2025, the number of shareholders was 25,700, a slight decrease of 0.11%, with an average of 28,196 shares held per shareholder, an increase of 0.11% [2]. - The fifth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 9.6492 million shares, a decrease of 1.53917 million shares from the previous period [3].

Investment Rating - The report maintains a "Buy" rating for the company [1][5] Core Views - The company reported a significant improvement in Q2 performance, with the innovative drug Didasinib entering a rapid growth phase [3][8] - Despite a year-on-year decline in revenue and net profit for the first half of 2025, the company showed a positive trend in its core business and R&D efforts [3][8] - The report emphasizes the potential for Didasinib's commercialization and the company's ongoing R&D investments as key drivers for future growth [5][8] Financial Summary - For the first half of 2025, the company achieved revenue of 2.017 billion RMB, a year-on-year decrease of 6.20%, while net profit was 388 million RMB, down 3.54% [3][8] - The company forecasts net profits of 843 million RMB for 2025, 965 million RMB for 2026, and 1.058 billion RMB for 2027, with corresponding EPS of 0.98, 1.12, and 1.23 RMB respectively [5][7] - The report projects a revenue growth rate of 9.1% for 2025 and 11.9% for 2026, with EBITDA expected to reach 1.215 billion RMB in 2025 [7][9] Business Performance - In Q2 2025, the company recorded a revenue of 1.060 billion RMB, a 10.92% increase from Q1, while net profit for the quarter was 225 million RMB, reflecting a 37.54% quarter-on-quarter growth [8] - The company’s core product, Didasinib, generated 55 million RMB in revenue during the first half of 2025, with over 1,500 hospitals now covered under its network [8] R&D and Pipeline - The company increased its R&D expenditure to 185 million RMB in the first half of 2025, focusing on key therapeutic areas such as mental health, cardiovascular, and digestive diseases [8] - Significant progress has been made in clinical trials for several innovative drugs, including JX11502 for schizophrenia and new treatments for cardiovascular diseases [8]

Core Viewpoint - Jingxin Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 62.32%, despite a recent decline of 2.03% on September 8 [1]. Financial Performance - For the first half of 2025, Jingxin Pharmaceutical reported revenue of 2.017 billion yuan, a year-on-year decrease of 6.20%, and a net profit attributable to shareholders of 388 million yuan, down 3.54% year-on-year [2]. - Cumulative cash dividends since the company's A-share listing amount to 2.11 billion yuan, with 801 million yuan distributed over the past three years [3]. Stock Market Activity - As of September 8, the stock price was 20.24 yuan per share, with a total market capitalization of 17.427 billion yuan [1]. - The stock has seen significant trading activity, with a turnover of 169 million yuan and a turnover rate of 1.14% on the same day [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with a net buy of 111 million yuan on July 4 [1]. Shareholder Information - As of June 30, 2025, the number of shareholders was 25,700, a slight decrease of 0.11% from the previous period [2]. - The average number of tradable shares per shareholder increased by 0.11% to 28,196 shares [2]. - Hong Kong Central Clearing Limited is the fifth-largest circulating shareholder, holding 9.6492 million shares, a decrease of 15.3917 million shares from the previous period [3].

Performance Summary - In the first half of 2025, the company achieved revenue of 2.017 billion yuan, a decrease of 6.20%, and a net profit attributable to shareholders of 388 million yuan, down 3.54%. The net profit excluding non-recurring items was 360 million yuan, an increase of 7.78%. The gross margin was 49.57%, down 2.00 percentage points, while the net margin was 19.45%, up 0.57 percentage points [1] - In Q2, the company reported revenue of 1.060 billion yuan, a year-on-year decrease of 2.64% but a quarter-on-quarter increase of 10.88%. The net profit attributable to shareholders was 225 million yuan, down 2.74% year-on-year but up 38.04% quarter-on-quarter. The net profit excluding non-recurring items was 214 million yuan, an increase of 20.36% year-on-year and 45.58% quarter-on-quarter, indicating significant operational improvement and steady enhancement of profitability [1] Business Segment Analysis - Finished drug revenue was 1.175 billion yuan, down 9.68%, with the pressure from price reductions largely absorbed. The commercialization of the new product, Dazatinib, made progress, with over 400 key medical institutions gaining access and achieving sales of 55 million yuan. The finished drug export business grew over 30% due to competitive pricing and stable quality [2] - Raw material drug revenue was 453 million yuan, down 9.59%, primarily affected by cyclical fluctuations in the raw material drug industry. The company continues to optimize its entire industry chain and processes to reduce costs and improve efficiency while accelerating international expansion for long-term stable development [2] - Medical device revenue was 349 million yuan, an increase of 12.01%, as the company continued to enhance its domestic market share and deepen cooperation with international strategic clients [2] Innovation Pipeline - The company is accelerating the development of its innovative pipeline, focusing on key therapeutic areas. In the psychiatric and neurological field, the self-developed first-class new drug JX11502 has completed Phase II clinical trials, and the production of the capsule form of Calirizine has been officially reported. In the cardiovascular field, the self-developed LP(a) lowering new drug is progressing through Phase I clinical trials. In the digestive field, the improved traditional Chinese medicine for ulcerative colitis has completed Phase II clinical trials, supporting the design and conduct of subsequent Phase III trials [2] Profit Forecast - The company is expected to achieve revenues of 4.627 billion yuan, 5.197 billion yuan, and 5.800 billion yuan for 2025-2027, with year-on-year growth rates of 11.3%, 12.3%, and 11.6%, respectively. The net profit attributable to shareholders is projected to be 800 million yuan, 934 million yuan, and 1.059 billion yuan, with year-on-year growth rates of 12.4%, 16.7%, and 13.4% [3] - The company maintains a "buy" rating based on the rapid growth of Dazatinib and a rich reserve of subsequent innovative pipelines [3]

Core Viewpoint - The report emphasizes the sustained high growth in the innovative pharmaceutical and medical device sectors, recommending continued investment in these areas [1]. Investment Highlights - The report maintains a recommendation for innovative pharmaceuticals and medical devices, highlighting the potential for value re-evaluation in the Pharma sector, with specific buy ratings for companies such as 恒瑞医药, 翰森制药, 三生制药, and 华东医药 [2]. - It continues to recommend Biopharma/Biotech companies that are gradually realizing their innovative pipelines and entering a performance growth phase, with buy ratings for 科伦博泰生物, 信达生物, 康方生物, 新诺威, 映恩生物, 京新药业, 微芯生物, 特宝生物, 我武生物, and 来凯医药 [2]. - The report also suggests investment in CXO and upstream pharmaceutical companies benefiting from innovation and recovery, maintaining buy ratings for 百普赛斯, 药明康德, 药明合联, 泰格医药, and 美诺华 [2]. - It recommends leading medical device companies expected to recover, with buy ratings for 微创医疗, 联影医疗, and 惠泰医疗 [2]. Market Performance - In the first week of September 2025, the A-share pharmaceutical sector outperformed the broader market, with the SW pharmaceutical and biotech index rising by 1.4% while the Shanghai Composite Index fell by 1.2% [3]. - Within the biopharmaceutical sector, the chemical preparations segment saw a notable increase of 4.5%, while biological products and medical services rose by 1.9% and 1.7%, respectively [3]. - The top-performing stocks included 海辰药业 (+28.7%), 长春高新 (+24.2%), and 百花医药 (+21.3%), while the worst performers were 舒泰神 (-24.0%), 广生堂 (-15.8%), and 塞力医疗 (-15.6%) [3]. - In the Hong Kong market, the healthcare sector also outperformed, with the Hang Seng Healthcare index rising by 7.0% and the biotech index by 7.3%, compared to a 1.4% increase in the Hang Seng Index [3]. - The top gainers in the Hong Kong market were 三叶草生物-B (+99%), 圣诺医药-B (+62%), and 加科思-B (+41%), while the biggest losers included 美中嘉和 (-11%), 科笛-B (-9%), and 思路迪医药股份 (-6%) [3]. - In the US market, the healthcare sector performed in line with the broader market, with the S&P Healthcare Select Sector Index increasing by 0.3%, matching the S&P 500's performance [4]. - The top gainers in the US healthcare sector included 德康医疗 (+7%), 生物基因 (+6%), and 环球健康服务 (+5%), while the largest declines were seen in KENVUE (-10%), REVVITY (-4%), and MOLINA HEALTHCARE (-3%) [4].